Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2021-09-28 00:00:00 ET · period of report 2021-09-23 · accession 0001209191-21-058002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-28 | 2021-09-23 | VRDN | Frazier Life Sciences Public Fund, L.P. | 10% | P - Purchase | $11.00 | +200.0K | 1.51M | +15% | +$2.20M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-23 | P | A | 200,000 | $11.00 | 1,505,200 | D | — | — | (F1) These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. and FHMLSP, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by Frazier Life Sciences Public Fund L.P., except to the extent of its pecuniary interest therein, if any. |